InVivo Therapeutics has appointed Robert J Rosenthal to the company’s Board of Directors, effective 8 November 2019. According to a press release, Rosenthal brings more than 25 years of experience to the InVivo Board as an accomplished executive and business leader in the biotechnology, therapeutics and medical device industries. With the addition of Rosenthal, InVivo’s Board has six members—five of whom are independent.
Rosenthal currently serves as chairman of the Board of Taconic Biosciences; a privately-held provider of research models for the pharmaceutical and biotech industry, where from 2014 to 2018 he also served as CEO. Furthermore, he also currently serves as a director of the Bruker Corporation—a publicly traded manufacturer of analytic instruments since 2015. Rosenthal has served since 2007 as a director of Safeguard Scientifics, a publicly-traded provider of capital for early- and growth-stage companies, and as chairman of its board of directors since May 2016. He also currently serves as a director of Galvanic Applied Sciences, a privately-held Canadian company, since 2013.
Ann Merrifield, InVivo’s chair of the Board of Directors, says: “Rosenthal’s deep experience across a range of corporate functions, from corporate development and business operations, to strategic planning and capital market transactions, will be a highly valuable addition to our Board as we guide the company forward toward its near- and long-term goals.”
Rosenthal comments: “I am excited to join the InVivo Board at this critical period in the company’s history, and I look forward to working together with the Board and the InVivo team as InVivo continues advancing down its clinical pathway to ultimately address an area of significant unmet need for spinal cord injury patients.”
Rosenthal has more than 25 years of experience in a variety of senior management positions with companies involved in the development of therapeutics, medical devices, diagnostics and life sciences tools, most recently including from 2010 through 2012 as president and CEO of IMI Intelligent Medical Implants, a medical technology company, and from 2005 through 2009 as president and CEO of Magellan Biosciences, a provider of clinical diagnostics and life sciences research tools. Earlier in his career, Rosenthal served in senior management positions at Perkin Elmer and Thermo Fisher Scientific, Inc.